Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

TY - JOUR

T1 - Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

AU - Kausik Kumar, Ray

AU - Ray, null

AU - Kausik Kumar, null

AU - Helen M., Colhoun

AU - Colhoun, null

AU - Michael, Szarek

AU - Helen M., null

AU - Marie, Baccara-Dinet

AU - Deepak L., Bhatt

AU - Szarek, null

AU - Vera A., Bittner

AU - Michael, null

AU - Andrzej J., Budaj

AU - Baccara-Dinet, null

AU - Marie, null

AU - Rafael, Diaz

AU - Shaun G., Goodman

AU - Bhatt, null

AU - Deepak L., null

AU - Bittner, null

AU - Vera A., null

AU - Budaj, null

AU - Andrzej J., null

AU - Diaz, null

AU - Rafael, null

AU - Goodman, null

AU - Shaun G., null

AU - Ērglis, Andrejs

PY - 2019

Y1 - 2019

UR - https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S2213858719301585

U2 - 10.1016/S2213-8587(19)30158-5

DO - 10.1016/S2213-8587(19)30158-5

M3 - Article

SN - 2213-8587

VL - 7

SP - 618

EP - 628

JO - The Lancet Diabetes and Endocrinology

JF - The Lancet Diabetes and Endocrinology

IS - 8

ER -